**Name of journal: *World Journal of Stem Cells***

**Manuscript NO: 42863**

**Manuscript Type: EDITORIAL**

**Human adult pluripotency: facts and questions**

Labusca l *et al.* controversies surrounding adult pluripotency

Luminita Labusca, Kaveh Mashayekhi

**Luminita Labusca,** National Institute of Research and Development for Advanced Technical Physics Iasi, Iasi 700349, Romania

**Kaveh Mashayekhi,** Systems Biomedical Informatics and Modeling, Frankfurt D-45367, Germany

**ORCID number:** Luminita Labusca (0000-0001-9635-6893); Kaveh Mashayekhi (0000-0002-3597-1160).

**Author contributions:** Labusca L conceived the manuscript and collected supportive literature; Mashayekhi K designed the bioinformatics input and revised the presented data and information.

**Conflict-of-interest statement:** All authors have no conflicts of interest to report.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Luminita Labusca, MD, PhD, Chief Doctor, Senior Researcher, Senior Scientist, Surgeon,** National Institute of Research and Development for Advanced Technical Physics Iasi, 47 Mangeron Boulevard, Iasi 700349, Romania. llabusca@phys-iasi.ro

**Telephone**: +40-74-9162219

**Received:** October 13, 2018

**Peer-review started:** October 15, 2018

**First decision:** November 1, 2018

**Revised:** November 6, 2018

**Accepted:** January 10, 2019

**Article in press:** January 10, 2019

**Published online:** January 26, 2019

**Abstract**

Cellular reprogramming and induced pluripotent stem cell (IPSC) technology demonstrated the plasticity of adult cell fate, opening a new era of cellular modelling and introducing a versatile therapeutic tool for regenerative medicine. While IPSCs are already involved in clinical trials for various regenerative purposes, critical questions concerning their medium- and long-term genetic and epigenetic stability still need to be answered. Pluripotent stem cells have been described in the last decades in various mammalian and human tissues (such as bone marrow, blood and adipose tissue). We briefly describe the characteristics of human-derived adult stem cells displaying *in vitro* and/or *in vivo* pluripotency while highlighting that the common denominators of their isolation or occurrence within tissue are represented by extreme cellular stress. Spontaneous cellular reprogramming as a survival mechanism favoured by senescence and cellular scarcity could represent an adaptative mechanism. Reprogrammed cells could initiate tissue regeneration or tumour formation dependent on the microenvironment characteristics. Systems biology approaches and lineage tracing within living tissues can be used to clarify the origin of adult pluripotent stem cells and their significance for regeneration and disease.

**Key words**: Human adult pluripotent stem cells; Induced pluripotent stem cells; Reprogramming; Cellular stress

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Several types of human adult pluripotent stem cells have been described. Their origin and role remain largely unknown. The elucidation of possible stress-induced pluripotency phenomena could enable regenerative as well as tumour-suppressive therapies.

**Citation**: Labusca L, Mashayekhi K. Human adult pluripotency: facts and questions. *World J Stem Cells* 2019; 11(1): 1-12

**URL:** https://www.wjgnet.com/1948-0210/full/v11/i1/1.htm

**DOI:** https://dx.doi.org/10.4252/wjsc.v11.i1.1

**Introduction**

During the development of multicellular organisms, cells evolve from the initial undifferentiated, totipotent state of the fertilized egg and early embryo to sequentially restricted states while gradually losing their differentiation potential. The capability of generating more committed progenitors is referred to as the degree of “potency” that defines the “stem” status of a cell. Adult organisms are composed of a large panel of differentiated cell types that accomplish various functions within the body. Among them, a variable amount of tissue-resident stem cells have been documented in various human tissues, accounting for tissue turnover and repair after injury. Tissue specific adult stem cells [such as mesenchymal stem cells (MSCs), neural stem cells, and haematopoietic stem cells] exist in dormant states in adult tissues and are thought to be lineage-restricted, meaning they only give rise to progeny of their tissue of origin. Differentiation implies epigenetic silencing of the so-called pluripotency genes and transcriptional activation of protein-coding genes with cell-type specific functions.

**Cellular reprogramming – challenging the dogma of locked adult differentiation**

The ultimate differentiated state associated with loss of cell division, which is known as terminal differentiation, was long considered irreversible. Seminal Nobel-winning research has gradually deconstructed this dogma. Envisaged by Nobel Prize-winner Hans Spemann in 1935, “the fantastical experiment”[1] was performed several decades later. Using the previously established nuclear transfer technology[2], somatic cell nuclei transferred to an enucleated egg cytoplasm were shown to generate a viable adult organism. The experiment confirmed that somatic, fully differentiated adult cells not only retain an intact full genome but can also revert to pluripotent stages under permissive conditions[3]. However, the locked differentiation dogma and definitive rolling down of the epigenetic Waddington landscape[4] was challenged even more dramatically several decades later. In 2006, Shinya Yamanaka used forced expression of several “pluripotency” transcription factors (Oct3/4, Klf4, Sox2 and c-Myc, which was later called the OKSM cocktail) to “reprogram” differentiated somatic cells (mouse fibroblasts) to a cellular status equivalent to embryonic counterparts [embryonic stem cells (ESCs)]. The “reprogrammed” elements, termed induced pluripotent stem cells (IPSCs) were similar to ES cells in morphology, proliferation, surface antigens, gene expression, epigenetic status of pluripotent cell-specific genes, and telomerase activity; the IPSCs were capable of generating various cell types in a teratoma assay and contributed to chimeric animals when injected into mouse blastocysts[5]. The IPSC reprogramming process was further refined to generate cells with potential for germ line transmission[6]. One year later, human fibroblast cells were converted to IPSCs, launching a new era of reprogramming technology with exciting implications in disease modelling and treatment[7]. The initial retroviral-based gene transfer of the OSKM factors was modified to increase reprogramming efficiency and decrease potential tumourigenicity. Non-integrating viruses, stabilized RNAs and proteins, and episomal plasmids are currently used to deliver integration-free reprogramming genes. A large panel of adult somatic or adult stem cells of various species and tissues of origin were shown to be reprogrammable to IPSCs. Some cell types such as neural stem cells required fewer transcription factors for reprogramming[8], while in some cases, small molecules can substitute for the forced expression of one or several OSKM factors[9]. Direct reprogramming of adult differentiated cells to adult cells of different lineages (*e.g.*, fibroblasts to neurons[10]) without conversion to intermediary pluripotent stages was further demonstrated. Using reprogramming methods, adult somatic cells could “go back” to pluripotent stages or directly convert to lineages with distinct developmental origins. Extreme somatic cell plasticity was therefore shown possible under defined *in vitro* conditions. A holistic systems biology approach was applied to existing large “-omic” datasets from pluripotent cell populations to discover genes important for pluripotency and cell reprogramming[11]. Bioinformatics analysis of several data bases on naïve and primed (pluripotent) ESCs revealed a network of functionally interrelated genes in which the OSKM factors are nodes (Table 1 and Figure 1). Contextual ontology enrichment and quantitative gene expression signatures revealed the mouse pluripotency gene interaction network, the hierarchical importance of genes and pathways, and their significance in pluripotency.

**Reprogramming at work**

IPSC-based or direct cell reprogramming further advanced to investigating the effect of somatic cell reprogramming *in vivo*.

Short term *in vivo* activation of OKSM factors in transgenic “reprogrammable” mice carrying a tetracycline-inducible OSKM polycistronic cassette crossed with progeria models reduced signs of premature ageing[12]. The same method improved recovery from metabolic disease and muscle injury in older wild-type mice**[**13]**.** Cellular epigenetic reprogramming after short-term cyclic *in vivo* activation of OKSM factors (termed partial reprogramming) does not cause tumour formation and probably acts by reverting epigenetic dysregulation associated with older age, offering a platform to study the disease of ageing. In other work, long-term induction of OKSM factors in reprogrammable mice lead to teratoma formation and IPSC induction in a large variety of tissues including haematopoietic lineages. Transcriptomic analysis showed that *in vivo*-produced IPSCs are more similar to ESCs compared to their *in vitro* counterparts; *in vivo-*produced IPSCs are also totipotent as they could generate all embryonic layers and trophectoderm, a property that ESCs are lacking[14]. Intriguingly, *in vivo* forced expression of OSKM factors, a process known to have low efficiency *in vitro*, triggers reprogramming of few cells and induces cellular senescence and apoptosis in many other surrounding cells *in vivo*. Ageing- and tissue injury-associated senescent cell-secreted factors (of which proinflammatory cytokine IL-6 plays a major role) improve the *in vivo* reprogramming process. A similar process might take place under physiological conditions when damage-driven senescent cells promote cell dedifferentiation during tissue repair[15]. *In vivo* direct reprogramming platforms are currently under intense scrutiny and may be the next generation of regenerative approaches for cardiac, neural, liver or pancreatic islet cells. Anti-aging interventions may be a possible outcome of direct somatic cell manipulation[16]. It is worth mentioning that spontaneous reprogramming mechanisms in mammalian organs do occur after injury. Using lineage tracing, several direct conversions were documented in mice. Adult hepatocytes were shown to spontaneously reprogram *in vivo* in biliary epithelial cells after toxic liver injury in a NOTCH-dependent mechanism[17]. Glucagon-producing alpha pancreatic cells converted to beta cells in a mouse model of diphtheria-induced acute selective beta cell loss[18]. Due to obvious ethical constraints, such mechanisms have not yet been documented in humans. Controversial reports about adult pluripotent stem cells in various human tissues prompts reconsideration of their origin and/or causative mechanisms.

**Adult pluripotent cell- types and controversies**

***Bone marrow-derived pluripotent cells***

Starting in the early 2000s, several reports about spontaneously occurring pluripotent cell types emerged**.** Derived from mice and human bone marrow by negative depletion of CD45 (+)/glycophorin (+) cells, multipotent adult progenitor cells (MAPCs) were reported to undergo triploblastic differentiation under defined conditions *in vitro*. MAPCs did not form teratomas, contributed to chimaera formation when injected into mouse blastocysts, and contributed to cardiac regeneration in severe combined immune-deficient (SCID) mice[19,20].Marrow-isolated adult multilineage-inducible cells derived from the bone marrow of vertebral bodies under low oxygen conditions were reported to be particularly efficient in differentiating into neural lineages without displaying features of pluripotency[21]. Very small embryonic-like cells (VSELs) were isolated from murine bone marrow by positive selection for the chemokine receptor CXCR4 and were shown to display features of embryonic cells (cell and nuclei size, chromatin characteristics, telomerase activity). The authors hypothesized that such cells with embryonic-like surface markers [stage-specific embryonic antigen (SSEA), OCT-4, and NANOG] could be epiblast-derived pluripotent cell remnants of embryonic developmental stages; these cells could be a less controversial source for regenerative approaches[22]. The existence of VSELs was challenged a couple of year later as other groups failed to replicate their isolation from bone marrow Remarkably, almost all reports of bone marrow-derived cells that claimed to retain embryonic-like stem cell features were isolated in modified culture conditions (such as low oxygen tension or serum deprivation). Arguments that such cells are early MSC progenitors or culture condition-modified MSCs have not been fully investigated to date[23]. MSCs derived from bone marrow as well as other sources (excluding adipose tissue) were shown to foster a population of SSEA-positive cells with enhanced expansive and clonogenic potential. Arguments that SSEA-positive cells are a culture artefact have not been addressed yet[24]. The existence of adult pluripotent cell populations proved hard to replicate, leading to doubt concerning the accuracy of the reported findings and concept of naturally occurring pluripotency. However, the diversity of reports on enigmatic cells with morphology similar to embryonic counterparts that were isolated under harsh conditions may signal that this is an unelucidated phenomena.

***Adipose-derived pluripotent cells***

Isolated from adipose-derived stromal vascular fraction, adipose-derived MSCs (ADSCs) were shown to differentiate to non-mesodermal lineages under special culture conditions *in vitro*[25]. Notably, the majority of non-mesenchymal lineage differentiation protocols involve an intermediary step including suspension culture, spheroid formation of intermediary progenitors and sometimes serum deprivation. Undifferentiated or *in vitro* pre-differentiated ADSCs were shown in several reports to contribute to liver, Schwann cell and glial cell regeneration[26]. The advent of IPSCs and the enthusiasm for their potential in generating patient-specific pluripotent cells for research and therapy seemed to throw the controversy of adult pluripotency into oblivion. However, two special cell types continue to capture research interest: multilineage differentiating stress-enduring cells (MUSE) and dedifferentiated fat cells.

***MUSE cells***

MUSE cells were initially identified by applying stressful culture conditions to several cell populations such as MSCs[27,28]; they have been further obtained from adipose tissue by positive immune-separation for the mesenchymal marker CD105 and SSEA-3[29]. MUSE cells are capable of triploblastic differentiation without tumour formation after *in vivo* injection into SCID mice; these were considered safer sources for pluripotent cells than ESCs or IPSCs[30]. With several distinctive properties *in vitro* and *in vivo*, MUSE cells display low telomerase activity and a normal karyotype. MUSE cells form distinctive clusters *in vivo* (the so-called M clusters) that resemble ES or IPSCs behaviours in similar conditions. These cells express pluripotent markers, such as NANOG, Oct3/4, Par-4, and Sox2, and are capable of spontaneous or induced expression of mesodermal, endodermal or ectodermal markers[31]. The low levels of cell proliferation and oncogenesis gene expression might account for their low proliferation and absence of tumourigenic activity, while the expression of gene clusters related to death and survival that are shared with non-mammalian species might represent a highly-conserved mechanism of cell survival during extreme conditions[32]. Several preclinical studies have reported their migratory potential due to expression of chemokines involved in cell homing and their capability to participate in liver, kidney, and neural regeneration in relevant animal models (for review see 30). Muse cells also have immunomodulatory properties in lipopolysaccharide-stimulated macrophages and antigen-challenged T-cell assays through downregulating the secretion of pro-inflammatory cytokines (interferon-γ and tumour necrosis factor-α); this effect is probably acquired by transforming growth factor-β1 expression that decreases the immune-regulatory activity through T-box transcription factors in T cells[33]. Interestingly, MUSE cells have been identified in very low numbers in the blood stream of early stage patients with acute stroke where they probably mobilized from bone marrow; MUSE cells have also been detected *in situ* and in post-mortem bone marrow samples harvested from subjects with severe conditions such as stroke and myocardial infarction[34]. Research to harness the therapeutic potential of such cells for regenerative applications is ongoing; however, their anatomical location in niches has not yet been identified. It is unclear whether induced or naturally occurring stressful conditions are sorting or generating MUSE cells through adaptative and potentially “reprogramming” mechanisms attempting regeneration after major insults.

Adipose tissue was one of the first sources reported for generating MUSE cells and another reportedly pluripotent adult human cell source is dedifferentiated adipose-derived cells (DFATs). Mature adipocytes isolated from adult human adipose tissue that are subjected to an *in vitro* dedifferentiation strategy (ceiling culture) revert to a more primitive phenotype and gain proliferative and differentiative abilities[35]. Indeed, DFATs were found to have triploblastic differentiation potential *in vitro* and do not generate teratomas when injected in immuno-deficient mice[36]. As opposed to ADSCs that are obtained by enzymatic digestion of adipose tissue and selection of plastic-adherent fibroblastoid elements, DFATs are homogenous populations. DFATS display surface markers for CD13, CD29, CD44, CD90, CD105, CD9, CD166 and CD54, and do not express CD14, CD31, CD34, CD45, CD66b, CD106, CD117, CD133, CD146, CD271, CD309, HLA-DR and alpha-smooth muscle cell actin; a fraction of DFATs also express SSEA-3[37]. Inter-donor and interspecies variability in the makeup of surface antigens has been reported. Combined with a Poly-D, L-lactic-co-glycolic acid scaffold, rat DFAT cells were able to regenerate periodontal tissue[38], opening exciting avenues for oral and maxillofacial tissue regeneration[39,40].

***Dedifferentiation as a source of adult pluripotent cells***

Mature adipocytes are not the only cells capable of dedifferentiation. Mature chondrocytes isolated from the well organized and highly structured cartilage ECM dedifferentiate while in monolayer culture. When expanded in MSC growth medium with or without fibroblast growth factor (FGF), costal chondrocytes express features of MSCs but retain their chondrogenic potential when injected *in vivo* for cartilage defects[41]. Cartilage progenitor cells with clonogenic and migratory potential reside in osteoarthritic cartilage but not in normal mature cartilage[42]. However, further reports identified surprisingly high levels of the stem cells markers Notch-1, Stro-1 and VCAM-1 in normal cartilage and in a stage- and zone-dependent manner in osteoarthritic (OA) cartilage[43]. Despite their controversial nature, these studies revealed the previously ignored dynamic activity of adult cellular cartilage elements that could be metabolic- and/or mechano-stimulation-dependent[44]. Hypothetically, cells with surface markers of pluripotency in adult cartilage could originate from dedifferentiated chondrocytes induced by metabolic and/or mechanical stress. Disturbances in these parameters might lead to abnormal cell clustering and ECM disorganization that synergizes to produce the progressive cartilage breakdown of OA. The fibrous remodelling of joint surfaces seen in advanced OA stages might represent an abnormal differentiation of such dedifferentiated adult chondrocytes.

Other cell types were shown to successfully dedifferentiate *in vitro* into multipotent or pluripotent progenitors. Adult human thyrocytes regained multipotency, proliferated and differentiated to neurogenic and adipogenic lineages *in vitro*[45]. Terminally differentiated keratinocytes were converted to their progenitor cells under FGF induction[46], while pancreatic islet cells morphed into duct-like progenitor cells under epidermal growth factor exposure[47]. It is noteworthy to mention that these reports involve *in vitro* cell populations. Isolation protocols require breakdown of ECM structures, a process commonly achieved by maintaining cells in monolayer cultures. Intriguingly, reports about *in vivo* formation of DFAT cells after induced local mechanical stress in mice might suggest that this process occurs as a natural adaptative mechanism to local stressful conditions[48]. Dedifferentiation, a common mechanism in plants and a limited number of vertebrates that is used for regeneration, involves switching off genes responsible for cell-specific functions, re-entering the cell cycle and proliferating, and switching on “pluripotency”-related genes. This might be a conserved phenomenon in mammalian organisms including humans. Several factors such as hypoxia, prolonged stress and injury are known to induce dedifferentiated cells after *in vitro* manipulation or *in vivo*. Factors that naturally induce such phenomena *in vivo* and the fate of the regenerative processes they launch need further investigation. Reports about dedifferentiation processes occurring in human malignant tumours, such as liposarcomas dedifferentiating to osteosarcomatous components[49] or soft tissue sarcomas to liposarcomas[50], reflect several rare situations of pathological dedifferentiation processes. Physiological lung myofibroblast dedifferentiation after tissue injury and inflammation accounts for adaptative apoptosis and bronchiolar re-epithelialization. During ageing, impaired dedifferentiation accounts for continued myofibroblast accumulation, excessive matrix deposition and subsequent interstitial lung fibrosis[51].

**STAP controversy**

In early 2014, a paper described a “unique cellular reprogramming phenomenon” of exposing adult differentiated cells to low pH. CD45-positive spleen lymphocytes from 1-week-old C57BL/6 mice carrying an Oct4-gfp transgene and adult cells derived from the brain, skin, muscle, fat, bone marrow, lung and liver that were transiently exposed to low pH were reported to acquire pluripotency *in vitro*. A portion of such cells, which the authors termed stimulus-triggered acquisition of pluripotency (STAP) stem cells, were shown to express pluripotency markers, differentiate to triploblastic lineages under specified conditions, and contribute to chimaeras and germline transmission when injected into mouse blastocysts. Compared to mouse ESCs, STAP cells displayed limited self-renewal capability in ES-specific media and did not form colonies in dissociated culture[52]. The authors hypostatised that “unknown cellular mechanisms” triggered by sublethal stress unlocked the cells from their differentiated state and allowed re-expression of pluripotency-related genes, reflecting early embryonic stages. Such phenomena do not likely occur *in vivo*—at least not in mammalian organisms—as presumed mechanisms block progression from the initial OCT-4 activation to further reprogramming. Several months later, the paper was retracted due to “errors classified as misconduct” by the institutional investigation committee[53]. The negative impact of the retraction was further combined with news about possible “honour suicide” of one of the senior authors. However, while the “multiple errors” could indeed impact the study reproducibility and the credibility of the reported data, they could not rule out the existence of the STAP phenomenon. Interestingly, a recent paper reported a method of preconditioning adult human umbilical cord blood-derived stem cells to increase survival after transplantation. Exposure to oxidative stress and serum deprivation increased cell resistance *in vitro*, possible pointing to an adaptative mechanism for cell survival[54].

**MSCs and the “stem cell state**”

The “classical model of hierarchical MSC differentiation depicts a MSC at the top of the potency ladder and subsequent progenies with reduced differentiation potential; this model was challenged by a report showing that murine bone marrow-derived MSCs clonally lost and regained differentiation ability. Fluctuating differentiation potential was even demonstrated at the single-cell level and was closely dependent on culture conditions. Oxygen tension and sparse culture density imposed by clonal expansion altered gene expression and the epigenetic profile that accounts for cell potency. Wnt activation in sparse cultured cells was directly visualized using a green fluorescent protein-tcf/lef reporter, while DNA microarray analysis revealed enrichment of histone methylation in EMT/MET-, MSC-, and Wnt-related genes; this process was found to be oxygen- and tension-dependent[55]. Isolation of cells away from the ECM and exposure to stressful culture conditions might influence mesenchymal cell potency. The authors discussed the potential stress-induced reversibility of cell fate in mammalian mesenchymal cells *in vivo* as a sort of adaptative mechanisms[56].

**Adult pluripotency and aging**

A decline in the reprogramming efficiency of cells derived from older donors in both mice and humans has been reported. However, IPSs with complete set of pluripotency markers as well as differentiation capabilities could be derived from older donors[57,58]. Several epigenetic barriers as well as the increased number of senescent cells, could quantitatively limit the reprograming process in older organisms, process that once initiated remains possible and qualitative. “Aging pathways” (IGF-1 pathway, mTOR,) or “longevity: related ones (AMPK or sirtuins) have been found to influence reprogramming and IPS generation (for review see 57). It is not clear, to date, how these functional and metabolic pathways are involved in potential spontaneous adult cell reprogramming. It is noteworthy to mention that all the above mentioned pathways are highly conserved modalities to sense multidirectional stress (such as energy status, DNA damage, protein damage, and hypoxia) and to orchestrate adaptative cellular responses[59]. Their connection and interference with potential spontaneous induced pluripotency needs to be further studied. Activation of Integrated stress response has been proposed as a mechanism for increased longevity in yeasts[60] and recently was found to facilitate human hematopoetic stem cells survival ans well as to mark leukemia stem cells[61] Cellular stress increasingly appears as a turning point between stemness and malignization in adult as well as aging organisms.

**Summary and some questions**

Reprogramming and the advent of Nobel–awarded IPSC technology has shifted our understanding of cell plasticity. Although previously thought to be “terminally” differentiated, adult cells have been shown to “climb back up” the potency hill to regain multiple differentiation potentials, similar to cells from early developmental stages. The revolutionary technology opened a promising era of cell manipulation for modelling and therapeutic use. IPSCs have gained momentum and are quickly moving towards clinical use for regeneration[57]. Several methods have been proposed to tackle genetic instability forced-reprogrammed cells; however, it their application and utility in designing IPSC-based therapies is not clear[58]. The medium- and long-term fates of therapeutic IPSCs and their progeny after implantation are still unclear, as are the influences on the safety and efficacy of regenerative therapies. The potentially safer alternatives of adult pluripotent stem cells (MUSE, DFAT) have not achieved similar impacts in research interest or clinical translation. Perhaps this is due to their variability, limited reproducibility of production conditions, and poorly explained mechanisms that account for their presence or appearance within adult tissues. It is not clear if adult pluripotent cells already exist in various tissues (such as bone marrow or adipose), or if they are a mere isolation or culture artefact. It remains unknown whether adult pluripotent cells are rare remnants of developmental stages in dormant states within tissues or spontaneously reprogrammed elements. The possibility that severe stress, cell loss or even ageing can induce human adult pluripotent cells both *in vitro* and *in vivo* cannot be ruled out and should warrant further investigation (Figure 2). Can adult “terminally differentiated” cells switch their fate and return to earlier developmental stages in human tissues and during isolation procedures under extreme conditions? If so, what is the threshold of “cellular stability?” Can protocols for steering cellular “destabilization” towards regeneration rather than malignancy be designed with computer modelling? What are the nature and gradient of “stressors” that potentially induce spontaneous reprogramming? What is the role of organism and cellular senescence in promoting or quenching such phenomena? What is the role of immune-mediated inflammation and the senescence-associated inflammatory background in promoting, controlling and halting *in vivo* reprogramming? What potential roles do spontaneously reprogrammed cells have in tissue regeneration and tumour formation? A closer and fundamental investigation of *in vivo* spontaneous-reprogramming phenomena in mammalian cells and humanized animal models could help answer these questions and impact both regenerative medicine and cancer research. Systems biology approaches could be used to discover key switches in biological pathways involved in adult pluripotency and may potentially derive targets for their identification within human tissues.

**Acknowledgements**

The authors wish to thank Dr. Florin Zugun-Eloae for his helpful counselling during the manuscript design.

**References**

1 **Spemann H,** Mangold H. "über Induktion von Embryonalanlagen durch Implantation artfremder Organisatoren". *Archiv für mikroskopische Anatomie und Entwicklungsmechanik* (in German) 1924; **100**: 599–638 [DOI: 10.1007/bf02108133]

2 **Briggs R**, King TJ. Transplantation of Living Nuclei From Blastula Cells into Enucleated Frogs' Eggs. *Proc Natl Acad Sci* USA 1952; **38**: 455-463 [PMID: 16589125 DOI: 10.1073/pnas.38.5.455]

3 **gurdon JB**. The developmental capacity of nuclei taken from differentiating endoderm cells of Xenopus laevis. *J Embryol Exp Morphol* 1960; **8**: 505-526 [PMID: 13709842 DOI: 10.1016/j.cell.2007.02.006]

4 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]

5 **Okita K**, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. *Nature* 2007; **448**: 313-317 [PMID: 17554338 DOI: 10.1038/nature05934]

6 **Takahashi K**, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007; **131**: 861-872 [PMID: 18035408 DOI: 10.1016/j.cell.2007.11.019]

7 **Kim J**, Efe JA, Zhu S, Talantova M, Yuan X, Wang S, Lipton SA, Zhang K, Ding S. Direct reprogramming of mouse fibroblasts to neural progenitors. *Proc Natl Acad Sci* USA 2011; **108**: 7838-7843 [PMID: 21521790 DOI: 10.1073/pnas.1103113108]

8 **Li W**, Zhou H, Abujarour R, Zhu S, Young Joo J, Lin T, Hao E, Schöler HR, Hayek A, Ding S. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. *Stem Cells* 2009; **27**: 2992-3000 [PMID: 19839055 DOI: 10.1002/stem.240]

9 **Li X**, Zuo X, Jing J, Ma Y, Wang J, Liu D, Zhu J, Du X, Xiong L, Du Y, Xu J, Xiao X, Wang J, Chai Z, Zhao Y, Deng H. Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons. *Cell Stem Cell* 2015; **17**: 195-203 [PMID: 26253201 DOI: 10.1016/j.stem.2015.06.003]

10 **Mashayekhi K,** Hall V, Freude K, Hoeffding MK, Labusca L, Hyttel P. Systems Biology and Stem Cell Pluripotency: Revisiting the Discovery of Induced Pluripotent Stem Cell. In: Kadarmideen HN, editor. Systems Biology in Animal Production and Health, Vol. 2. Springer, 2016: 127-154 [DOI: 10.1007/978-3-319-43332-5]

11 **Carey BW**, Markoulaki S, Beard C, Hanna J, Jaenisch R. Single-gene transgenic mouse strains for reprogramming adult somatic cells. *Nat Methods* 2010; **7**: 56-59 [PMID: 20010831 DOI: 10.1038/nmeth.1410]

12 **Ocampo A**, Reddy P, Martinez-Redondo P, Platero-Luengo A, Hatanaka F, Hishida T, Li M, Lam D, Kurita M, Beyret E, Araoka T, Vazquez-Ferrer E, Donoso D, Roman JL, Xu J, Rodriguez Esteban C, Nuñez G, Nuñez Delicado E, Campistol JM, Guillen I, Guillen P, Izpisua Belmonte JC. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. *Cell* 2016; **167**: 1719-1733.e12 [PMID: 27984723 DOI: 10.1016/j.cell.2016.11.052]

13 **Abad M**, Mosteiro L, Pantoja C, Cañamero M, Rayon T, Ors I, Graña O, Megías D, Domínguez O, Martínez D, Manzanares M, Ortega S, Serrano M. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. *Nature* 2013; **502**: 340-345 [PMID: 24025773 DOI: 10.1038/nature12586]

14 **Mosteiro L**, Pantoja C, Alcazar N, Marión RM, Chondronasiou D, Rovira M, Fernandez-Marcos PJ, Muñoz-Martin M, Blanco-Aparicio C, Pastor J, Gómez-López G, De Martino A, Blasco MA, Abad M, Serrano M. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. *Science* 2016; **354**: aaf4445 [PMID: 27884981 DOI: 10.1126/science.aaf4445]

15 **Taguchi J**, Yamada Y. In vivo reprogramming for tissue regeneration and organismal rejuvenation. *Curr Opin Genet Dev* 2017; **46**: 132-140 [PMID: 28779646 DOI: 10.1016/j.gde.2017.07.008]

16 **Yanger K**, Zong Y, Maggs LR, Shapira SN, Maddipati R, Aiello NM, Thung SN, Wells RG, Greenbaum LE, Stanger BZ. Robust cellular reprogramming occurs spontaneously during liver regeneration. *Genes Dev* 2013; **27**: 719-724 [PMID: 23520387 DOI: 10.1101/gad.207803.112]

17 **Thorel F**, Népote V, Avril I, Kohno K, Desgraz R, Chera S, Herrera PL. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. *Nature* 2010; **464**: 1149-1154 [PMID: 20364121 DOI: 10.1038/nature08894]

18 **Dimomeletis I**, Deindl E, Zaruba M, Groebner M, Zahler S, Laslo SM, David R, Kostin S, Deutsch MA, Assmann G, Mueller-Hoecker J, Feuring-Buske M, Franz WM. Assessment of human MAPCs for stem cell transplantation and cardiac regeneration after myocardial infarction in SCID mice. *Exp Hematol* 2010; **38**: 1105-1114 [PMID: 20621157 DOI: 10.1016/j.exphem.2010.06.013]

19 **Jiang Y**, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* 2002; **418**: 41-49 [PMID: 12077603 DOI: 10.1038/nature00870]

20 **Tatard VM**, D'Ippolito G, Diabira S, Valeyev A, Hackman J, McCarthy M, Bouckenooghe T, Menei P, Montero-Menei CN, Schiller PC. Neurotrophin-directed differentiation of human adult marrow stromal cells to dopaminergic-like neurons. *Bone* 2007; **40**: 360-373 [PMID: 17085092 DOI: 10.1016/j.bone.2006.09.013]

21 **Kucia M**, Zuba-Surma EK, Wysoczynski M, Wu W, Ratajczak J, Machalinski B, Ratajczak MZ. Adult marrow-derived very small embryonic-like stem cells and tissue engineering. *Expert Opin Biol Ther* 2007; **7**: 1499-1514 [PMID: 17916043 DOI: 10.1517/14712598.7.10.1499]

22 **Miyanishi M**, Mori Y, Seita J, Chen JY, Karten S, Chan CK, Nakauchi H, Weissman IL. Do pluripotent stem cells exist in adult mice as very small embryonic stem cells? *Stem Cell Reports* 2013; **1**: 198-208 [PMID: 24052953 DOI: 10.1016/j.stemcr.2013.07.001]

23 **Prockop DJ**. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. *Mol Ther* 2009; **17**: 939-946 [PMID: 19337235 DOI: 10.1038/mt.2009.62]

24 **Zuk P.** Adipose-Derived Stem Cells in Tissue Regeneration: A Review. *ISRN Stem Cells* 2013; **2013**: 35 [DOI: 10.1155/2013/713959]

25 **Lv FJ**, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. *Stem Cells* 2014; **32**: 1408-1419 [PMID: 24578244 DOI: 10.1002/stem.1681]

26 **Kuroda Y**, Kitada M, Wakao S, Nishikawa K, Tanimura Y, Makinoshima H, Goda M, Akashi H, Inutsuka A, Niwa A, Shigemoto T, Nabeshima Y, Nakahata T, Nabeshima Y, Fujiyoshi Y, Dezawa M. Unique multipotent cells in adult human mesenchymal cell populations. *Proc Natl Acad Sci* USA 2010; **107**: 8639-8643 [PMID: 20421459 DOI: 10.1073/pnas.0911647107]

27 **Kitada M**, Wakao S, Dezawa M. Muse cells and induced pluripotent stem cell: implication of the elite model. *Cell Mol Life Sci* 2012; **69**: 3739-3750 [PMID: 22527723 DOI: 10.1007%2Fs00018-012-0994-5]

28 **Heneidi S**, Simerman AA, Keller E, Singh P, Li X, Dumesic DA, Chazenbalk G. Awakened by cellular stress: isolation and characterization of a novel population of pluripotent stem cells derived from human adipose tissue. *PLoS One* 2013; **8**: e64752 [PMID: 23755141 DOI: 10.1371/journal.pone.0064752]

29 **Simerman AA**, Perone MJ, Gimeno ML, Dumesic DA, Chazenbalk GD. A mystery unraveled: nontumorigenic pluripotent stem cells in human adult tissues. *Expert Opin Biol Ther* 2014; **14**: 917-929 [PMID: 24745973 DOI: 10.1517/14712598.2014.900538]

30 **Fisch SC**, Gimeno ML, Phan JD, Simerman AA, Dumesic DA, Perone MJ, Chazenbalk GD. Pluripotent nontumorigenic multilineage differentiating stress enduring cells (Muse cells): a seven-year retrospective. *Stem Cell Res Ther* 2017; **8**: 227 [PMID: 29041955 DOI: 10.1186/s13287-017-0674-3]

31 **Alessio N**, Squillaro T, Özcan S, Di Bernardo G, Venditti M, Melone M, Peluso G, Galderisi U. Stress and stem cells: adult Muse cells tolerate extensive genotoxic stimuli better than mesenchymal stromal cells. *Oncotarget* 2018; **9**: 19328-19341 [PMID: 29721206 DOI: 10.18632/oncotarget.25039]

32 **Gimeno ML**, Fuertes F, Barcala Tabarrozzi AE, Attorressi AI, Cucchiani R, Corrales L, Oliveira TC, Sogayar MC, Labriola L, Dewey RA, Perone MJ. Pluripotent Nontumorigenic Adipose Tissue-Derived Muse Cells have Immunomodulatory Capacity Mediated by Transforming Growth Factor-β1. *Stem Cells Transl Med* 2017; **6**: 161-173 [PMID: 28170177 DOI: 10.5966/sctm.2016-0014]

33 **Hori E**, Hayakawa Y, Hayashi T, Hori S, Okamoto S, Shibata T, Kubo M, Horie Y, Sasahara M, Kuroda S. Mobilization of Pluripotent Multilineage-Differentiating Stress-Enduring Cells in Ischemic Stroke. *J Stroke Cerebrovasc Dis* 2016; **25**: 1473-1481 [PMID: 27019988 DOI: 10.1016/j.jstrokecerebrovasdis.2015.12.033]

34 **Matsumoto T**, Kano K, Kondo D, Fukuda N, Iribe Y, Tanaka N, Matsubara Y, Sakuma T, Satomi A, Otaki M, Ryu J, Mugishima H. Mature adipocyte-derived dedifferentiated fat cells exhibit multilineage potential. *J Cell Physiol* 2008; **215**: 210-222 [PMID: 18064604 DOI: 10.1002/jcp.21304]

35 **Jumabay M**, Boström KI. Dedifferentiated fat cells: A cell source for regenerative medicine. *World J Stem Cells* 2015; **7**: 1202-1214 [PMID: 26640620 DOI: 10.4252/wjsc.v7.i10.1202]

36 **Miyazaki T**, Kitagawa Y, Toriyama K, Kobori M, Torii S. Isolation of two human fibroblastic cell populations with multiple but distinct potential of mesenchymal differentiation by ceiling culture of mature fat cells from subcutaneous adipose tissue. *Differentiation* 2005; **73**: 69-78 [PMID: 15811130 DOI: 10.1111/j.1432-0436.2005.07302004.x]

37 **Jumabay M**, Abdmaulen R, Ly A, Cubberly MR, Shahmirian LJ, Heydarkhan-Hagvall S, Dumesic DA, Yao Y, Boström KI. Pluripotent stem cells derived from mouse and human white mature adipocytes. *Stem Cells Transl Med* 2014; **3**: 161-171 [PMID: 24396033 DOI: 10.5966/sctm.2013-0107]

38 **Akita D**, Kano K, Saito-Tamura Y, Mashimo T, Sato-Shionome M, Tsurumachi N, Yamanaka K, Kaneko T, Toriumi T, Arai Y, Tsukimura N, Matsumoto T, Ishigami T, Isokawa K, Honda M. Use of Rat Mature Adipocyte-Derived Dedifferentiated Fat Cells as a Cell Source for Periodontal Tissue Regeneration. *Front Physiol* 2016; **7**: 50 [PMID: 26941649 DOI: 10.3389/fphys.2016.00050]

39 **Kishimoto N**, Honda Y, Momota Y, Tran SD. Dedifferentiated Fat (DFAT) cells: A cell source for oral and maxillofacial tissue engineering. *Oral Dis* 2018; **24**: 1161-1167 [PMID: 29356251 DOI: 10.1111/odi.12832]

40 **Lee J**, Lee JY, Chae BC, Jang J, Lee E, Son Y. Fully Dedifferentiated Chondrocytes Expanded in Specific Mesenchymal Stem Cell Growth Medium with FGF2 Obtains Mesenchymal Stem Cell Phenotype In Vitro but Retains Chondrocyte Phenotype In Vivo. *Cell Transplant* 2017; **26**: 1673-1687 [PMID: 29251111 DOI: 10.1177/0963689717724794]

41 **Koelling S**, Kruegel J, Irmer M, Path JR, Sadowski B, Miro X, Miosge N. Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. *Cell Stem Cell* 2009; **4**: 324-335 [PMID: 19341622 DOI: 10.1016/j.stem.2009.01.015]

42 **Grogan SP**, Miyaki S, Asahara H, D'Lima DD, Lotz MK. Mesenchymal progenitor cell markers in human articular cartilage: normal distribution and changes in osteoarthritis. *Arthritis Res Ther* 2009; **11**: R85 [PMID: 19500336 DOI: 10.1186/ar2719]

43 **Labusca L**, Mashayekhi K. The role of progenitor cells in osteoarthritis development and progression. *Curr Stem Cell Res Ther* 2015; **10**: 90-98 [PMID: 24975620 DOI: 10.2174/1574888X09666140630102202]

44 **Suzuki K**, Mitsutake N, Saenko V, Suzuki M, Matsuse M, Ohtsuru A, Kumagai A, Uga T, Yano H, Nagayama Y, Yamashita S. Dedifferentiation of human primary thyrocytes into multilineage progenitor cells without gene introduction. *PLoS One* 2011; **6**: e19354 [PMID: 21556376 DOI: 10.1371/journal.pone.0019354]

45 **Sun X**, Fu X, Han W, Zhao Y, Liu H, Sheng Z. Dedifferentiation of human terminally differentiating keratinocytes into their precursor cells induced by basic fibroblast growth factor. *Biol Pharm Bull* 2011; **34**: 1037-1045 [PMID: 21720010 DOI: 10.1248/bpb.34.1037]

46 **Hanley SC**, Assouline-Thomas B, Makhlin J, Rosenberg L. Epidermal growth factor induces adult human islet cell dedifferentiation. *J Endocrinol* 2011; **211**: 231-239 [PMID: 21933872 DOI: 10.1530/JOE-11-0213]

47 **Liao Y**, Zeng Z, Lu F, Dong Z, Chang Q, Gao J. In vivo dedifferentiation of adult adipose cells. *PLoS One* 2015; **10**: e0125254 [PMID: 25901360 DOI: 10.1371/journal.pone.0125254]

48 **Yoshida A**, Ushiku T, Motoi T, Shibata T, Fukayama M, Tsuda H. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant. *Am J Surg Pathol* 2010; **34**: 1361-1366 [PMID: 20697254 DOI: 10.1097/PAS.0b013e3181ebcc45]

49 **Wibmer C**, Leithner A, Zielonke N, Sperl M, Windhager R. Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. *Ann Oncol* 2010; **21**: 1106-1111 [PMID: 19858086 DOI: 10.1093/annonc/mdp415]

50 **Glasser SW**, Hagood JS, Wong S, Taype CA, Madala SK, Hardie WD. Mechanisms of Lung Fibrosis Resolution. *Am J Pathol* 2016; **186**: 1066-1077 [PMID: 27021937 DOI: 10.1016/j.ajpath.2016.01.018]

51 **Ueda M**, Becker AE, Naruko T, Kojima A. Smooth muscle cell de-differentiation is a fundamental change preceding wound healing after percutaneous transluminal coronary angioplasty in humans. *Coron Artery Dis* 1995; **6**: 71-81 [PMID: 7767506 DOI: 10.1097/00019501-199501000-00011]

52 **Obokata H**, Wakayama T, Sasai Y, Kojima K, Vacanti MP, Niwa H, Yamato M, Vacanti CA. Stimulus-triggered fate conversion of somatic cells into pluripotency. *Nature* 2014; **505**: 641-647 [PMID: 24476887 DOI: 10.1038/nature12968]

53 **Obokata H**, Wakayama T, Sasai Y, Kojima K, Vacanti MP, Niwa H, Yamato M, Vacanti CA. Retraction: Stimulus-triggered fate conversion of somatic cells into pluripotency. *Nature* 2014; **511**: 112 [PMID: 24990753 DOI: 10.1038/nature13598]

54 **Bashiri H**, Amiri F, Hosseini A, Hamidi M, Mohammadi Roushandeh A, Kuwahara Y, Jalili MA, Habibi Roudkenar M. Dual Preconditioning: A Novel Strategy to Withstand Mesenchymal Stem Cells against Harsh Microenvironments. *Adv Pharm Bull* 2018; **8**: 465-470 [PMID: 30276143 DOI: 10.15171/apb.2018.054]

55 **Shoshani O**, Zipori D. Stress as a fundamental theme in cell plasticity. *Biochim Biophys Acta* 2015; **1849**: 371-377 [PMID: 25038585 DOI: 10.1016/j.bbagrm.2014.07.006]

56 **Shoshani O**, Ravid O, Massalha H, Aharonov A, Ovadya Y, Pevsner-Fischer M, Leshkowitz D, Zipori D. Cell isolation induces fate changes of bone marrow mesenchymal cells leading to loss or alternatively to acquisition of new differentiation potentials. *Stem Cells* 2014; **32**: 2008-2020 [PMID: 24715711 DOI: 10.1002/stem.1719]

57 **Mahmoudi S**, Brunet A. Aging and reprogramming: a two-way street. *Curr Opin Cell Biol* 2012; **24**: 744-756 [PMID: 23146768 DOI: 10.1016/j.ceb.2012.10.004]

58 **Yener Ilce B**, Cagin U, Yilmazer A. Cellular reprogramming: A new way to understand aging mechanisms. *Wiley Interdiscip Rev Dev Biol* 2018; **7**: [PMID: 29350802 DOI: 10.1002/wdev.308]

59 **Haigis MC**, Yankner BA. The aging stress response. *Mol Cell* 2010; **40**: 333-344 [PMID: 20965426 DOI: 10.1016/j.molcel.2010.10.002]

60 **Postnikoff SDL**, Johnson JE, Tyler JK. The integrated stress response in budding yeast lifespan extension. *Microb Cell* 2017; **4**: 368-375 [PMID: 29167799 DOI: 10.15698/mic2017.11.597]

61 **van Galen P**, Mbong N, Kreso A, Schoof EM, Wagenblast E, Ng SWK, Krivdova G, Jin L, Nakauchi H, Dick JE. Integrated Stress Response Activity Marks Stem Cells in Normal Hematopoiesis and Leukemia. *Cell Rep* 2018; **25**: 1109-1117.e5 [PMID: 30380403 DOI: 10.1016/j.celrep.2018.10.021]

62 **Mandai M**, Kurimoto Y, Takahashi M. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. *N Engl J Med* 2017; **377**: 792-793 [PMID: 28834478 DOI: 10.1056/NEJMc1706274]

63 **International Stem Cell Initiative.**, Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, Beil S, Benvenisty N, Ben-Yosef D, Biancotti JC, Bosman A, Brena RM, Brison D, Caisander G, Camarasa MV, Chen J, Chiao E, Choi YM, Choo AB, Collins D, Colman A, Crook JM, Daley GQ, Dalton A, De Sousa PA, Denning C, Downie J, Dvorak P, Montgomery KD, Feki A, Ford A, Fox V, Fraga AM, Frumkin T, Ge L, Gokhale PJ, Golan-Lev T, Gourabi H, Gropp M, Lu G, Hampl A, Harron K, Healy L, Herath W, Holm F, Hovatta O, Hyllner J, Inamdar MS, Irwanto AK, Ishii T, Jaconi M, Jin Y, Kimber S, Kiselev S, Knowles BB, Kopper O, Kukharenko V, Kuliev A, Lagarkova MA, Laird PW, Lako M, Laslett AL, Lavon N, Lee DR, Lee JE, Li C, Lim LS, Ludwig TE, Ma Y, Maltby E, Mateizel I, Mayshar Y, Mileikovsky M, Minger SL, Miyazaki T, Moon SY, Moore H, Mummery C, Nagy A, Nakatsuji N, Narwani K, Oh SK, Oh SK, Olson C, Otonkoski T, Pan F, Park IH, Pells S, Pera MF, Pereira LV, Qi O, Raj GS, Reubinoff B, Robins A, Robson P, Rossant J, Salekdeh GH, Schulz TC, Sermon K, Sheik Mohamed J, Shen H, Sherrer E, Sidhu K, Sivarajah S, Skottman H, Spits C, Stacey GN, Strehl R, Strelchenko N, Suemori H, Sun B, Suuronen R, Takahashi K, Tuuri T, Venu P, Verlinsky Y, Ward-van Oostwaard D, Weisenberger DJ, Wu Y, Yamanaka S, Young L, Zhou Q. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. *Nat Biotechnol* 2011; **29**: 1132-1144 [PMID: 22119741 DOI: 10.1038/nbt.2051]

**P-Reviewer:** Kim YB, Oltra E, Scarfì S **S-Editor:** Ma YJ **L-Editor:** A **E-Editor:** Tan WW

**Specialty type:** Cell and tissue engineering

**Country of origin:** Romania

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**G:\[0000]applications\2018\grant pluripotency\Figure 1 .tif**

**Figure 1 Flux diagram of the top 10 ranked genes related to pluripotency (interaction data obtained from GNCPro, SABiosciences).** Interactions: downregulation (green arrow), upregulation (red arrow), predicted transcription factor regulation (magenta arrow), predicted protein interaction (blue line), regulation (black arrow), other types of regulation (grey line). See the electronic version for colour figures. Boxes outlined in black represent the target genes, and light grey boxes their immediate neighbours. Adapted from Mashayekhi *et al*[11].

G:\[0000]applications\2018\grant pluripotency\figure 2.tif

**Figure 2 The possibility that severe stress, cell loss or even ageing can induce human adult pluripotent cells both *in vitro* and *in vivo* cannot be ruled out and should warrant further investigation.** A: A normal human dermal fibroblast (NHDF) cell line after 48 h of intentional CO2 absence in the incubator. The cells modified their morphologic characteristics and adopted the culture appearance of pluripotent cells; B: Modified NHDF cells 28 d after stress; C: non-exposed NHDF cells; D: modified NHDF cells 73 d after stress.

**Table 1 Pathway population**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cell lineage identification** | **Hedgehog** | **P53** | **WNT targets** | **WNT** | **Cell cycle** | **VEGFs** | **Embryonic stem cells** | **Stem cell signalling** | **Homeobox** | **Stem cell TF** | **EMT** | **Jak-STAT** | **Stem cells** | **Terminal diff marker** | **Notch sig** | **Epigen chrom remod fact** | **Notch targets** | **Total number of pathways** |
|  |  | **+** | **+** | **+** |  |  | **+** |  |  | **+** |  | **+** | **+** |  |  |  |  | 7 |
|  |  |  | **+** | **+** |  |  |  | **+** |  |  | **+** |  |  |  | **+** |  |  | 5 |
|  |  |  |  |  |  |  | **+** | **+** |  | **+** | **+** | **+** |  |  |  |  |  | 5 |
| **+** |  |  | **+** |  |  |  | **+** |  |  | **+** |  |  | **+** |  |  |  |  | 5 |
| **+** |  |  | **+** |  |  |  | **+** |  |  | **+** |  |  |  |  |  |  |  | 4 |
| **+** |  |  | **+** |  |  |  |  |  |  |  |  | **+** |  |  |  |  | **+** | 4 |
|  |  | **+** |  |  | **+** |  |  |  |  |  |  | **+** |  |  | **+** |  |  | 4 |
|  |  |  |  |  |  |  | **+** | **+** |  |  |  | **+** |  |  |  |  |  | 3 |
|  | **+** |  |  |  |  |  |  | **+** |  | **+** |  |  |  |  |  |  |  | 3 |
|  |  |  |  |  |  |  |  | **+** | **+** | **+** |  |  |  |  |  |  |  | 3 |
|  |  |  |  |  |  |  | **+** |  |  | **+** |  |  |  |  |  |  |  | 2 |
|  |  |  |  |  |  |  |  |  | **+** | **+** |  |  |  |  |  |  |  | 2 |
|  |  |  |  |  | **+** |  |  | **+** |  |  |  |  |  |  |  |  |  | 2 |
|  |  |  |  |  |  |  |  |  |  | **+** |  |  |  |  |  | **+** |  | 2 |
|  |  | **+** |  |  | **+** |  |  |  |  |  |  |  |  |  |  |  |  | 2 |
|  |  |  |  |  |  |  |  |  |  | **+** |  |  |  |  |  |  |  | 1 |
|  |  |  |  |  |  |  | **+** |  |  |  |  |  |  |  |  |  |  | 1 |
|  |  |  |  |  |  |  | **+** |  |  |  |  |  |  |  |  |  |  | 1 |
| 3 | 1 | 3 | 5 | 2 | 3 | 0 | 8 | 6 | 2 | 10 | 2 | 5 | 2 | 0 | 2 | 1 | 1 | **56** |

A list of genes selected from the 1100 upregulated genes in naïve *vs* primed-state embryonic stem cellss. The genes are ranked in ascending order based on the number of scores in different pluripotent-related cell pathways. (+) indicates that the gene is associated with the pluripotency-related pathways listed. Grey highlights the top 10 genes based on their involvement in > 3 pluripotent-related pathways. Three of the 4 Yamanaka factors fall in this list and are marked in bold with\*. (Adapted from Mashayekhi *et al*[11]).